Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice

Int J Mol Sci. 2019 Mar 13;20(6):1273. doi: 10.3390/ijms20061273.

Abstract

The risk of heart failure (HF) is prominently increased in patients with type 2 diabetes mellitus. The objectives of this study were to establish a murine model of diabetic cardiomyopathy induced by feeding a high-sugar/high-fat (HSHF) diet and to evaluate the effect of reconstituted HDLMilano administration on established HF in this model. The HSHF diet was initiated at the age of 12 weeks and continued for 16 weeks. To investigate the effect of reconstituted HDLMilano on HF, eight intraperitoneal administrations of MDCO-216 (100 mg/kg protein concentration) or of an identical volume of control buffer were executed with a 48-h interval starting at the age of 28 weeks. The HSHF diet-induced obesity, hyperinsulinemia, and type 2 diabetes mellitus. Diabetic cardiomyopathy was present in HSHF diet mice as evidenced by cardiac hypertrophy, increased interstitial and perivascular fibrosis, and decreased myocardial capillary density. Pressure-volume loop analysis indicated the presence of both systolic and diastolic dysfunction and of decreased cardiac output in HSHF diet mice. Treatment with MDCO-216 reversed pathological remodelling and cardiac dysfunction and normalized wet lung weight, indicating effective treatment of HF. No effect of control buffer injection was observed. In conclusion, reconstituted HDLMilano reverses HF in type 2 diabetic mice.

Keywords: diabetic cardiomyopathy; obesity; type 2 diabetes mellitus.

MeSH terms

  • Animals
  • Apolipoprotein A-I / pharmacology*
  • Cardiomegaly / drug therapy
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Type 2 / complications
  • Diabetic Cardiomyopathies / drug therapy*
  • Diet, High-Fat / adverse effects
  • Drug Combinations
  • Female
  • Fibrosis / drug therapy
  • Heart Failure / drug therapy*
  • Lipoproteins, HDL / pharmacology*
  • Mice
  • Mice, Inbred C57BL
  • Obesity / complications
  • Phosphatidylcholines / pharmacology*
  • Systole / drug effects

Substances

  • Apolipoprotein A-I
  • Drug Combinations
  • Lipoproteins, HDL
  • MDCO-216
  • Phosphatidylcholines